{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-25-000079","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.001642+00:00","generated_at":"2026-05-17T13:58:19.073829+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Instil Bio Q2 net loss $3.24/share; cash $103.6M; IND cleared for '2510","bullets":["Cash, equivalents, marketable securities and long-term investments of $103.6M as of June 30, 2025; funded beyond 2026.","Net loss per share $3.24 (GAAP) and $2.88 (non-GAAP) for Q2 2025, vs $2.29 and $1.57 year-ago.","R&D expenses $6.7M in Q2 2025; in-process R&D expenses $10.0M; G&A expenses $6.2M.","U.S. IND for AXN-2510/IMM2510 cleared; U.S. trial initiation expected before end of 2025.","Appointed Jamie Freedman, M.D., Ph.D. as Chief Medical Officer in June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-25-000079","json":"https://secwatch.observer/filing/0001789769-25-000079.json","markdown":"https://secwatch.observer/filing/0001789769-25-000079.md","text":"https://secwatch.observer/filing/0001789769-25-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000079/0001789769-25-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976925000079/til-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:58:19.073829+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}